The influence of secreted factors and extracellular vesicles in ovarian cancer metastasis
European Journal of Cancer, Supplement · Published 2020-08-01 · DOI 10.1016/j.ejcsup.2019.09.001
Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.ejcsup.2019.09.001
Abstract
Ovarian cancer cells mainly metastasise within the peritoneal cavity, the lethal consequence of tumour progression in this cancer type. Classically, changes in tumour cells, such as epithelial to mesenchymal transition, involve the down-regulatinon of E-cadherin, activation of extracellular proteases and integrin-mediated adhesion. However, our current understanding of ovarian tumour progression suggests the implication of both intrinsic and extrinsic factors. It has been proposed that ovarian cancer metastases are a consequence of the crosstalk between cancer cells and the tumour microenvironment by soluble factors and extracellular vesicles. Characterisation of the alterations in both the tumour cells and the surrounding microenvironment has emerged as a new research field to understand ovarian cancer metastasis. In this mini review, we will summarise the most recent findings, focusing our attention on the role of secreted factors and extracellular vesicles in ovarian cancer metastasis.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2020
Related articles
- Urothelial carcinoma management in elderly or unfit patients · European Journal of Cancer, Supplement · 2016 · Same journal
- Inflammation and immunity in ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal
- DNA damaging agents in ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal
- Cell proliferation inhibitors and apoptosis promoters · European Journal of Cancer, Supplement · 2020 · Same journal
- Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study · European Journal of Cancer, Supplement · 2021 · Same journal
- Biosimilars: Extrapolating the evidence. A roundtable discussion · European Journal of Cancer, Supplement · 2015 · Same journal
- Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients? · European Journal of Cancer, Supplement · 2021 · Same journal
- Insight updating of the molecular hallmarks in ovarian carcinoma · European Journal of Cancer, Supplement · 2020 · Same journal
- Anti-angiogenic therapy for ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal
- Rare ovarian tumours. Other treatments for ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal